Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: A nationwide prospective inception cohort study

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Sada, Ken ei ^a   Yamamura, Masahiro ^b   Harigai, Masayoshi ^c   Fujii, Takao ^d   Takasaki, Yoshinari ^e   Amano, Koichi ^f   Fujimoto, Shouichi ^g   Muso, Eri ^h   Murakawa, Yohko ⁱ   Arimura, Yoshihiro ^j   Makino, Hirofumi ^k   Dobashi, Hiroaki ^l   Yamada, Hidehiro ^m   Yamagata, Kunihiro ⁿ   Ito, Satoshi ⁿ   Homma, Sakae ^o   Wada, Takashi ^p   Kumagai, Shunichi ^q   Hirahashi, Junichi ^r   Banno, Shogo ^s   Hasegawa, Hitoshi ^t   Yumura, Wako ^u   Matsubara, Hiroaki ^v   Yoshida, Masaharu ^w   Katsuoka, Kensei ^x   Ogawa, Noriyoshi ^y   more..

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

^g UNIVERSITY OF MIYAZAKI   (Japan)

^h Kitano Hospital   (Japan)

ⁱ SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^j KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^l KAGAWA UNIVERSITY   (Japan)

^m ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ UNIVERSITY OF TSUKUBA   (Japan)

^o TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^p KANAZAWA UNIVERSITY   (Japan)

^q KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^r UNIVERSITY OF TOKYO   (Japan)

^s NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^t EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^u JICHI MEDICAL UNIVERSITY   (Japan)

^v KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^w TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^x KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^y HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Antineutrophil cytoplasmic antibody associated vasculitis; Cyclophosphamide; Glucocorticoid; Granulomatosis with polyangiitis; Inception cohort; Microscopic polyangiitis; Prospective cohort

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRANULOMATOSIS; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; REMISSION; SURVIVAL RATE; VERY ELDERLY; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; GRANULOMATOSIS WITH POLYANGIITIS; JAPAN; KIDNEY FAILURE, CHRONIC; PATHOLOGY; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

AGED; AGED, 80 AND OVER; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MICROSCOPIC POLYANGIITIS; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84955749820     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0815-y     Document Type: Article

References (29)

1. Jennette J, Falk R, Bacon P, Basu N, Cid M, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1-11.
2. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222-7.
3. Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford). 2011;50:1916-20.
4. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000;43:414-9.
5. Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther. 2014;16:R101.
6. Liu LJ, Chen M, Yu F, Zhao MH, Wang HY. Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology (Oxford). 2008;47:708-12.
7. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310-7.
8. Ntatsaki E, Carruthers D, Chakravarty K, D'Cruz D, Harper L, Jayne D, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014.
9. Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM. Cyclophosphamide pulse therapy in Wegener's granulomatosis. Nephrol Dial Transplant. 1991;6:531-5.
10. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM. 1997;90:401-9.
11. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997;40:2187-98.
12. Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol. 2012;22:394-404.
13. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66:605-17.
14. ICH Steering Committee. ICH harmonized tripartite guidline. Clinical safety data management: definitions and standards for expedited reporting; 1994.
15. Furuta S, Chaudhry AN, Hamano Y, Fujimoto S, Nagafuchi H, Makino H, et al. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol. 2014;41:325-33.
16. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64:3452-62.
17. Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908-18.
18. Sugiyama K, Sada KE, Kurosawa M, Wada J, Makino H. Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. Clin Exp Nephrol. 2013;17:51-8.
19. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44.
20. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670-80.
21. de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol. 2013;8:1709-17.
22. Hauer HA, Bajema IM, Van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002;62:1732-42.
23. Li ZY, Chang DY, Zhao MH, Chen M. Predictors of treatment resistance and relapse in ANCA-associated vasculitis: a study of 439 cases in a single Chinese center. Arthritis Rheumatol. 2014;66:1920-6.
24. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012;7:240-7.
25. Walsh M, Flossmann O, Berden A, Westman K, Hoglund P, Stegeman C, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:542-8.
26. Wada T, Hara A, Arimura Y, Sada KE, Makino H. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol. 2012;39:545-51.
27. Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken). 2010;62:1166-73.
28. Charlier C, Henegar C, Launay O, Pagnoux C, Berezne A, Bienvenu B, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009;68:658-63.
29. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74:177-84.